Navigation Links
Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
Date:9/11/2012

FORT WORTH, Texas, Sept. 11, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the initiation of a Phase III clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802-247 plus compression therapy compared to those receiving vehicle control plus compression therapy over the 12-week treatment period.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

"Following the favorable results achieved in our Phase IIb trial, we are very pleased to be initiating the Phase III study for this first-in-class cell-based therapy," commented Bert Slade, MD, FAAAAI, Chief Medical Officer at Healthpoint Biotherapeutics. "In addition to this multicenter North American study, our development strategy includes a second multicenter trial, which we plan to initiate next year at centers across Europe."

The North American study is a randomized, double-blind study involving subjects 18 years of age and older with venous leg ulcers of at least 6 weeks but not more than 24 months duration. The ulcers must be between 2 cm2 and 12 cm2 in area at presentation. Approximately 440 subjects will be enrolled across 45 investigational centers in the United States and Canada.

"As is evidenced by our ongoing $60 million investment in a state-of-the-art cell sciences research and manufacturing facility at our headquarters in Fort Worth, Healthpoint Biotherapeutics is committed to advancing the development of our lead pipeline candidate," said Travis E. Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "We look forward to the results of the pivotal registration studies for HP802-247 and, ultimately, to bringing a significant advance in the treatment of venous leg ulcers to the millions of patients suffering from this debilitating condition."

For more information about the HP802-247 North American clinical trial, go to www.LegSoreStudy.com, or call 866-910-2020 to speak with a clinical trial recruitment specialist.

About HP802-247

HP802-247 is an investigational allogeneic living human cell bioformulation that consists of two components that are sprayed sequentially on the wound bed at the time of treatment: a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts.

Based on in vitro studies, HP802-247 is believed to release various growth factors and cytokines into the micro-environment of the wound. These living cells are anticipated to interact with the patient's own cells to stimulate wound healing.  HP802-247 has been designed to deliver a defined cell ratio (keratinocyte:fibroblasts) to support optimal tissue regeneration.

Positive results for a Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers were recently published in The Lancet. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States and Canada. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection, and skin irritation.  The safety profile of the active groups was similar to the vehicle control.   

About Venous Leg Ulcers

Venous leg ulcers are increasingly common and costly, and a cause of prolonged suffering for patients. These wounds are caused by swelling and inflammation secondary to blockage or backflow in the veins of the legs. Many venous ulcers fail to heal even after 3 months of standard treatment and develop into chronic, non-healing wounds. Based on an estimated figure of 2.5 million venous leg ulcers in the United States alone and a study of actual direct treatment costs of $9,685 per person, the annual cost of treating these wounds is likely in the many billions of dollars. Accordingly, the availability of innovative and more effective treatment strategies for such high-risk wounds could provide tremendous benefits to both patients and society.

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is centered around next-generation bioactive therapies for the treatment of chronic wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® (becaplermin) Gel 0.01%. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®.  Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpointbio.com.

HEALTHPOINT and related logo, SANTYL, THE WOUND INSTITUTE, THEWOUNDINSTITUTE.COM and REGRANEX are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc.


'/>"/>
SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
2. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
5. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
6. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
7. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
8. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
9. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
10. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
11. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... DUBLIN , Jan 18, 2017 Research ... Nausea and Vomiting Drugs Market 2017-2021" report to their offering. ... The global ... the period 2017-2021. Global Thoracic Surgery Market 2017-2021, ... from industry experts. The report covers the market landscape and its ...
(Date:1/18/2017)... Jan. 18, 2017 In China ... is where the Upgrade of China,s ... 13th Five-Year Plan for Economic and Social Development of ... Five-Year Plan), and the state council of the ... national strategic emerging industry development plan, identifying medical devices as ...
(Date:1/18/2017)... , January 18, 2017 Ximbio, a ... share research resources, has opened its first North American headquarters ... ... an expansion for Ximbio following its launch in October 2014 ... Technology (CRT), the commercialization arm of the foundation Cancer Research ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a ... business owners in central Maryland and the DC region, is inaugurating a charity event ... people nationally every year, making it the #1 killer in America. However, heart disease ...
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that Mr. Michael Merges, Director of Strategic Growth, ... be held at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, ...
(Date:1/18/2017)... ... 2017 , ... The Hear the World Foundation, a Sonova ... of cochlear implants. In February 2017, the first three children with profound hearing ... leading an independent life. This engagement builds on the support the Hear the ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... dental problems ranging from gum disease to enamel erosion, and those dental problems ... Massachusetts Department of Public Health, many pregnant women are failing to get the ...
Breaking Medicine News(10 mins):